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Summary 
Emicizumab is a bispecific antibody that activates FX to FXa in the absence of FVIII. It has 
been shown to reduce bleeding episodes in people with haemophilia A complicated by a 
FVIII inhibitor. Despite the protection against bleeds some breakthrough bleeds are 
inevitable and these may require additional haemostatic treatment. Emicizumab has been 
associated with severe adverse events when co-administered with activated prothrombin 
complex concentrate. To minimise the risk of adverse events The UK Haemophilia Centre 
Doctors’ OrgaŶisatioŶ issues the followiŶg updated interim guidance to its Inhibitor 
Guidelines for managing patients receiving Emicizumab based on the limit published 
information available in February 2018.  
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Background 
Emicizumab® (Roche, Basel, Switzerland) is a bispecific antibody that binds to factor 
(F)IX/IXa and FX/FXa and activates FX to FXa in the absence of FVIII [1]. It has been shown to 
reduce bleeding episodes in people with haemophilia A complicated by a FVIII inhibitor [2]. 
Despite the reduction in annualised bleed rate, some breakthrough bleeds are inevitable 
and these may require additional haemostatic treatment. 
Co-administration of Emicizumab and activated prothrombin complex concentrate (aPCC, 
FEIBA®, Shire, Dublin, Ireland) has been associated with thrombotic microangiopathy (TMA), 
venous thrombosis and skin necrosis. These adverse events have been observed when aPCC 
is used for more than one day and at cumulative doses higher than 100 u/kg/day [2]. The 
number of reported patients treated with Emicizumab and aPCC at doses lower than 100 
u/kg/day is small, therefore, the risk of adverse events at lower doses of aPCC cannot be 
assumed to be zero, especially if aPCC is used for more than 24 hours. To date there have 
been no TMA or thrombotic adverse events associated with the co-administration of 
Emicizumab and recombinant FVIIa (rFVIIa, Novoseven®, Novo Nordisk, Bagsværd, 
Denmark) or FVIII concentrates but the number of patients treated for bleeds on 
Emicizumab remains relatively small and the risk of thrombotic events with these agents 
cannot be excluded. Based on theoretical considerations, co-administration of FVIII and 
Emicizumab may be associated with a lower risk of thrombosis than aPCC and rFVIIa [3] but 
this remains to be confirmed in published clinical studies.  
It is plausible that the venous thrombotic events are related to increased thrombin 
generation associated with the bispecific antibody interacting with coagulation factors in 
aPCC [3]. One of the venous thrombotic events was associated with consumptive 
coagulopathy. The mechanism that causes TMA and skin necrosis is unclear. 
In order to minimise the risk of adverse events associated with the use of Emicizumab the 
UK Haeŵophilia CeŶtre Doctors’ OrgaŶisation issues the following interim update to its 
current inhibitor guidelines [4] based on the limited published data available in February 
2018 [5]. These guidelines are a consensus statement and have been written from the 
perspective of UK treaters and clinicians. Other countries may need to revise this guidance 
as appropriate to their health care system and interim advice was issued in the USA in Nov 
2017 [6]. It is recognised that these guidelines may require revision as new data become 
available. 
 
General advice   
In the UK, Emicizumab should only be prescribed to patients with FVIII inhibitors by 
Comprehensive Care Haemophilia Centres (CCC) with expertise in treating patients with 
inhibitors. The CCC should take full responsibility for the ongoing management and 
monitoring of the Emicizumab. Patients receiving Emicizumab should have 24 hour access to 
clinicians with expertise in treating haemophilia with an inhibitor for advice on treatment of 
bleeding episodes. 
Bypassing agents should be stopped the day before Emicizumab is started. All aPCC (FEIBA®) 
should be removed froŵ the patieŶt’s hoŵe and returned to the CCC before Emicizumab is 
started. An updated patient-held Bleeding Disorder Card should be issued.  
Emicizumab interferes with the one stage FVIII assay and chromogenic FVIII assays using 
human coagulation factors. Once Emicizumab has been started a chromogenic FVIII assay 
using reagents containing bovine coagulation factors must be used to monitor FVIII 
replacement. The Bethesda assay utilising a bovine-based FVIII chromogenic assay must be 
used [5].  
Before Emicizumab is started, samples should be taken to measure anti-human and anti-
porcine FVIII inhibitor titres.  
All treatment with Emicizumab, bypassing agents and FVIII must be recorded, including 
treatment given in hospital. In the UK this should be through Haemtrack [6] and reported to 
the National Haemophilia Database (NHD) through routine mechanisms.  
Adverse events [4,8] must be reported both to regulators through appropriate channels 
and, in the UK, to the NHD adverse event reporting site. Biochemical changes compatible 
with TMA should also be reported. Data should be collected prospectively on safety and 
efficacy especially in relation to co-prescription to better inform future guidelines. 
Emicizumab has a long half-life and the treatment recommendations described in this 
guidance should be observed for 6 months after stopping the drug.  
 
Treatment of bleeding episodes 
Bleeds should not be treated with aPCC unless no other alternative is available.  
In patients receiving Emicizumab, for less severe mucosal bleeds tranexamic acid alone may 
be sufficient. Tranexamic acid should not be used in conjunction with aPCC but can be used 
with rFVIIa. 
Treatment with additional haemostatic therapy should only be started if a bleed has 
definitely occurred or after a significant mechanism of injury. In patients receiving 
Emicizumab, minor bleeds may resolve without additional haemostatic therapy. If the 
symptoms of a bleed are minor or equivocal then advice should be sought from the CCC 
before starting treatment. In some cases assessment of the symptoms and signs may be 
needed before deciding whether to initiate additional haemostatic therapy. Definite or 
severe bleeds should continue to be treated as soon as possible and advice sought from the 
CCC. 
First line treatment of bleeds that require haemostatic replacement therapy should be with 
rFVIIa and patients should be closely observed for symptoms of venous and arterial 
thrombosis. To reduce the risk of thrombosis, the initial dose of rFVIIa should not exceed 90 
µg/kg. Both Emicizumab and rFVIIa cause thrombin generation and rFVIIa given at doses of 
45 µg/kg 4 hourly may be efficacious for some bleeds. It is acknowledged that these dosing 
schedules are not based on published evidence and may need to be revised as more data 
become available. The schedule is a pragmatic balance between risk of adverse events and 
the need to adequately treat bleeds. If lower doses or frequencies of rFVIIa do not result in 
an adequate haemostasis response, rFVIIa should be increased to 90 µg/kg 2 hourly before 
it is assumed to have failed. The total treatment period may be shortened in some cases 
because Emicizumab is likely to give partial protection against bleed recurrence. Clinicians 
and patients/parents should agree the exact dose and frequency of rFVIIa that can be used 
at home and when advice should be sought from the CCC if the bleed does not resolve.  
If a bleed does not respond to full dose rFVIIa [9] and the anti-human FVIII inhibitor titre is 
low, human FVIII can be considered to treat bleeds, although it is recognised that this may 
lead to an amnestic response and an increased inhibitor titre. A chromogenic assay using 
reagents containing bovine coagulation factors should be used to ensure that adequate FVIII 
levels have been achieved because responses to FVIII will be unpredictable in the presence 
of an inhibitor. 
Recombinant porcine factor VIII (rpFVIII, Obizur®, Shire, Dublin, Ireland) is not licensed for 
treatment of congenital haemophilia A. However, if the porcine inhibitor is low, treatment 
of bleeding episodes with rpFVIII can be considered if a bleed has not responded to rFVIIa 
and aPCC cannot be used at doses less than <100 u/kg/day or the patient develops clinical 
or laboratory signs of TMA or thrombosis whilst receiving aPCC. 
If a severe bleed has not responded to rFVIIa and other treatment options are not available 
then use of aPCC should be considered. We recommend that all treatment with aPCC should 
be initiated and controlled by a senior clinician at a CCC. The first dose of aPCC should not 
exceed 50 u/kg, even for a severe bleed. A dose of 25 u/kg may be efficacious for some 
bleeds. A second dose of 25-50 u/kg can be considered on day one, if necessary. These 
dosing schedules are based on consensus and may need to be revised as more data are 
published.  
If further treatment with aPCC is required the cumulative dose should not usual exceed 100 
U/kg/day. If the bleed does not respond to aPCC at doses less than 100 u/kg/day, and no 
other treatment options are available, then higher doses of aPCC can be considered if the 
treating clinician decides that the risk of not treating the bleed clearly outweighs the risk of 
adverse events. 
In patients treated with Emicizumab and aPCC, clinicians should have a high level of 
suspicion for TMA and venous and arterial thrombotic events. If treatment with aPCC is 
required for more than one dose, the patient should be admitted to hospital and assessed 
twice a day for laboratory evidence of TMA. This includes FBC to look for a decrease in 
haemoglobin and/or platelets, blood film for red cell fragmentation, reticulocytes, D-dimer, 
renal function, LDH and haptoglobin. If laboratory monitoring suggests the development of 
TMA, aPCC should be stopped.  
 
The reported episode of skin necrosis was observed in an area of skin that had been treated 
with local ice therapy. Whether this was causally related or co-incidental is not known, 
however, clinicians should be cautious about the use of ice therapy in patients receiving 
concomitant Emicizumab and aPCC.  
 
Immune tolerance induction 
There are no data on the use of Emicizumab prophylaxis to prevent bleeding episodes 
during immune tolerance induction (ITI) and the safety of Emicizumab in this situation is 
unproven. Emicizumab should only be considered during ITI for patients with significant and 
frequent breakthrough bleeds. The dose of FVIII should be tailored to avoid high FVIII levels 
which will occur as FVIII tolerance is approached.  
 
Surgery 
Data describing surgery in patients receiving Emicizumab are very limited and responses are 
unpredictable. Consideration should be given to delaying non-urgent cases until further data 
are available, especially for major surgery.  
An abstract described 29 surgeries in 22 patients receiving Emicizumab. Of these 29 
surgeries, 15 were dental extractions or central venous access devices (CVAD) procedures, 
12 were other minor procedures and 2 were major procedures. No bypassing agent cover 
was given in 19 cases whilst bypassing agents were used in 10 cases [10]. 
Of the 19 surgeries managed without bypassing agents there were 5 (26%) post-operatives 
bleeds of which 3 followed dental extractions. One of these 5 post-operative bleeds 
required rFVIIa treatment, this was an arthroscopic orthopaedic procedure including 
synovectomy and debridement. 
Of the 10 cases that were treated with a bypassing agent at the time of surgery (9 rFVIIa and 
one aPCC, doses or frequencies not reported) there were two post-operative bleeds and 
both required rFVIIa treatment [10].  
A further case report described a hip replacement performed following 100 µg/kg rFVIIa 
before the procedure and 80 µg/kg 3 hourly following the procedure. Despite this treatment 
a thigh haematoma developed on the first post-operative day which required FVIII 
replacement by continuous infusion. Of note, thrombin generation parameters were in the 
normal range whilst the patient was on Emicizumab prophylaxis and in the peri-operative 
period [11].    
For minor surgery such as CVAD procedures and dental extractions consideration may be 
given to undertaking the procedure using tranexamic acid without additional haemostatic 
cover. There should be close clinical review for bleeding and rFVIIa used to manage surgical 
related bleeding if necessary. Alternatively, a single dose of rFVIIa, between 45-90 µg/kg can 
be used with further treatment as required. In patients with low titre inhibitors human or 
recombinant porcine FVIII are options but clinicians should take into consideration that an 
amnestic response may occur preventing subsequent use of these agents and centres will 
need to be able to monitor FVIII levels with appropriate assays in real time. 
Based on very limited data, major orthopaedic procedures are likely to require additional 
haemostatic replacement therapy although this does not guarantee adequate haemostasis. 
We suggest delaying non-urgent major surgery until more data are available.   
There are no data to support the use of thrombin generation or thromboelastography to 
monitor haemostasis during surgery with Emicizumab.  
 
Summary recommendations 
Emicizumab should only be prescribed by Comprehensive Care Haemophilia Centres (CCC). 
Patients should have 24 hour access to clinicians with expertise in treating haemophilia 
with an inhibitor. 
All treatment with Emicizumab, rFVIIa, aPCC and FVIII must be recorded, in the UK this 
would be on Haemtrack, with safety and efficacy data collected prospectively.  
Bypassing agents should be stopped 24 hours before Emicizumab is started and all home 
supplies of aPCC should be withdrawn.  
An anti-human and anti-porcine FVIII inhibitor titre should be measured before 
Emicizumab is started. 
First line treatment of bleeds should be rFVIIa. Human FVIII or recombinant porcine FVIII 
may be options if the bleed does not resolve with rFVIIa and the human or porcine 
inhibitor titres are low.  
Bleeding episodes should not be treated with aPCC unless no other option is available. If 
used, the initial dose of aPCC should not exceed 50 u/kg. 
If a second dose of aPCC is required the patient should be admitted to hospital for 
surveillance for the TMA.  
Clinical haemostasis during surgery in patients receiving Emicizumab is unpredictable and 
data are very limited. Non-urgent, major surgery should be deferred until more data are 
available. 
Due to the long half-life of Emicizumab, these treatment recommendations should be 
followed for 6 months after the drug has been stopped.  
Once Emicizumab has been started a chromogenic assay using reagents containing bovine 
coagulation factors must be used to monitor FVIII replacement. The Bethesda assay 
utilising a bovine reagent-based FVIII chromogenic assay must be used. 
 
Conclusion 
Emicizumab has been shown to decrease the number of bleeds and improve the quality of 
life for patients with haemophilia A and an inhibitor. Severe adverse events have occurred 
when Emicizumab is used in association with aPCC. This guidance document aims to give 
advice to minimise the risk of adverse events. It is recognised that as new data emerge this 
guidance will need to be updated. UKHCDO has set a review date of no later than January 
2019 but recognise that early updates may be necessary.  
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